– Dragonfly Therapeutics announces publication of preclinical data supporting DF6002, its extended half-life cytokine IL-12, as a promising treatment for cancer
The publication titled “An optimized IL-12-Fc widens its therapeutic window, achieving strong activity against mouse tumors at tolerable drug doses” was published April 13 in Cell Press’s Med.
WALTHAM, Mass., April 17, 2023/PRNewswire/ — Dragonfly Therapeutics, Inc., a clinical-stage biotechnology company developing new immunotherapies, today announced the April 13 release of preclinical data in Med by Cell Press that support DF6002 as a promising treatment option for cancer patients. DF6002 is Dragonfly’s novel extended half-life interleukin-12 (IL-12) cytokine immunotherapy, currently in Phase 1 dose-escalation clinical development progressing successfully in patients as monotherapy and in combination with nivolumab, in the US. USA and in Europe.
Historically, systemic IL-12 cytokine therapy was associated with severe toxicities due to its narrow therapeutic index. Dragonfly preclinical data demonstrates that DF6002 is well tolerated when administered systemically and results in potent antitumor responses in multiple preclinical models as monotherapy and in combination with checkpoint inhibitors. Dragonfly’s novel DF6002 IL-12 is designed to prolong the half-life, thereby altering the pharmacodynamic response profile of IL-12 and broadening its therapeutic index. “We are excited about these findings, which provide compelling evidence supporting our ongoing Phase I clinical trial evaluating the safety and tolerability of DF6002 in patients with advanced solid tumors,” said Joseph Eid, MD, president of research and development at Dragonfly. “Given the encouraging profile we have seen in both preclinical and clinical models to date, we are accelerating the development of DF6002 in a variety of indications and combinations.”
About DF6002
DF6002, Dragonfly’s extended half-life cytokine IL-12, is an investigational immunotherapy being evaluated alone and in combination with nivolumab in participants with locally advanced or metastatic solid tumors (NCT04423029). DF6002 is a monovalent IL-12 immunoglobulin Fc fusion protein proposed to achieve strong antitumor efficacy by establishing an inflammatory tumor microenvironment necessary for productive antitumor responses. DF6002 has the potential to stimulate effective antitumor immunity in patients who are not eligible for or do not respond adequately to current therapies. DF6002 is the most advanced in a portfolio of cytokines that Dragonfly is developing to address a large unmet need in patients with advanced cancer.
About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to the discovery, development and commercialization of therapies that use its novel bispecific antibody technology to harness the body’s immune system and deliver innovative treatments to patients. In addition to its wholly owned clinical assets and multiple clinical assets with partners, Dragonfly has a large pipeline of wholly owned preclinical candidates developed using its proprietary platforms, as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb in a wide range of disease areas.
For more information, visit: www.dragonflytx.com https://www.linkedin.com/company/dragonfly-therapeutics-inc./ https://twitter.com/dragonflytx
DRAGONFLY MEDIA CONTACT: Anne Deconinck | anne@dragonflytx.com
Logo – https://mma.prnewswire.com/media/390962/Dragonfly_Therapeutics_Inc_Logo.jpg
View original content: https://www.prnewswire.com/news-releases/dragonfly-therapeutics-anuncia-la-publicacion-de-datos-preclinicos-que-respaldan-a-df6002-301799172.html
